Q4 2020 Knight Therapeutics Inc Earnings Call

Jeff Palm

Nash

Jak and by your program you need out of your assistance during today's program your stress Stars.

Good morning. Ladies and gentlemen. My name is Gretchen and I will be your operator today. Welcome to Knight Therapeutics Inc. Twenty twenty fourth quarter Financial results conference call before turning over to Jonathan Ross Goodman. CEO of night listeners are reminded that portions of today's discussion May by their nature necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements the company considers the assumptions on which these forward-looking statements are based to be reasonable at the time. They were prepared but cautious that these assumptions regarding the future events many of which are beyond the control of the company and its subsidiaries May ultimately prove to be incorrect the company claims any intention or obligation to update or revise any forward-looking statements, whether a result of new information future events, except as required by law.

We would also like to remind your new questions.

During today's call will be taken from analysts only. Should there be any further questions, please contact nights investor relations department via email to info page or via phone at 514-678-8930. I would like to remind everyone that this call is being recorded today, March 25th, 221,000 like to turn the meeting over to your host for today's call Jonathan Ross Goodman, please go ahead. Mr. Goodman.

Good morning, everyone and welcome to Knight Therapeutics fourth quarter and year-end 2020 conference call. I'm joined during today's call with Murasaki our president and Chief Operating Officer among khouri our newly promoted Chief business officer. Yeah arvind itana our Chief Financial Officer and Jeff Martin our VP commercial the past year was a transformative your for night with the completion of the acquisition of Grupo biotoscana, despite the challenges due to COVID-19. We continue to progress our integration while advancing our pickup portfolio on both Canada and Latin America. We've received regulatory approvals from Health Canada for Australia and back seat and received regulatory approval and bemma and Halliburton in Ecuador. We continue to focus on

We continue to focus on our mission to acquire in license develop and commercialize Innovative medicines and high-quality branded treatments to improve the health of patients and Latin America and Canada right now like to turn the call over to Samara to walk through the corporate update.

Thank you, Jonathan and good morning. Everyone. First of all, I'd like to extend my own Yahoo and congratulate them all on her promotion to but Chief business officer. I'm always on his first hire at 9 a.m. And during the last seven years she has done an amazing job in leading Knights corporate and Business Development as well as corporate strategy. I'm always instrumental in the diligence and negotiation of the acquisition of the month and in twenty-twenty like the mandatory tender offer and navigated the complexities of Brazilian Securities laws to get it done. I also want to welcome Jeff to team night. Jeff has been working with us will be the last year too in harmonizing commercial efforts, including Marketing sales and Market access throughout Latin America. Jeff has over twenty years of experience in pharmaceutical reps and marketing Market access and sales and comes to us from Novartis where he had several where he held several executive roles at Novartis in Canada, which is part of the lack Ken regen God.

As well as Australia over the last year we have been focused on managing through the pandemic while continuing to integrate as we've discussed before biotoscana was an amalgamation of four different companies two of which were Regional licensing organizations and to branded generic companies in Argentina further. The operations ran as individual countries operating independently over the last year. We have focused our efforts in bringing all five companies including night together. We have made great strides in our commercial leadership teams at both the regional and country-level. We've expanded our business development organization and have made progress and killing key roles with top talent in finance.

Jerry 20

Twenty-One, my focus will be to continue to strengthen our scientific Affairs and Manufacturing structures. In addition. We will continue to implement systems and processes which will bolster efficiencies course in compliance as we get through integration. We are building a stronger platform for continued growth.

Turning now to the twenty-twenty ncib which we launched in July of last year under this ncib night can purchase up to ten point nine million, chairs until July 2021 month during the year. We purchased nine hundred forty-four thousand, shares for a knack for aggregate cash consideration of approximately 5.5 million dollars so far in 2021, we have purchased an additional two point nine million, shares and an average price of $5.25 per share 4-4 aggregate cash consideration of 15.2 million dollars.

In addition late last year. We saw the short form. They shall prospectus which enables night to offer for sale and issue up to $360 in common shares subscription receipts and debt Securities from time to time for a period of twenty five months during which the Shelf remains valid. I will return the call over to a mall for an update on BD activity.

Thank you signora as previously mentioned an important part of our effort in 2020 went towards completing the fender also process in Brazil that resulted in the acquisition a hundred percent of g b t and the third quarter followed by dealer staying in both Brazil and Luxembourg in parallel to completing the acquisition. We dedicated our efforts to strengthening our banquet facilities and ensuring coverage and expertise across our expanded region today. Our team is spread across four countries and is led by our new head of development defines a very young age was based in South Paulo in Brazil Saverio joins nights in August of last year. He has over twenty years of experience in Pharma having spent the last twelve years at one of the largest Brazilian pharmaceutical companies.

As I say it's a very old both Business Development and activities that resulted in the launch of over 300 branded generics and Innovative products across Latin America.

On the portfolio site be completed Market assessments across our key countries to identify and prioritize key therapeutic areas and further refine our portfolio strategy. We walk in you to focus in oncology hematology infectious diseases Immunology gastrointestinal and central nervous system.

We will pursue a three-pronged strategy to build our portfolio first. We will pursue the acquisition of innovative Legacy products from Big Pharma second rule and license Innovative products and third will develop our branded generics portfolio for select Latin American country. I will now turn the call over to Jeff to go over the product update.

Thank you very much at all. It is my pleasure to provide the first update on our products as well as our commercial structure which continue to advance in this year of integration starting with our structure as Samara mentioned focused our efforts on integrating and regionalizing our strategic planning process and strengthened our teams both by promoting internal Talent as well as recruiting externally ask for a products. We continue to advance our portfolio throughout our region in the first quarter of 2020. We launched cresemba and Brazilian for the treatment of invasive aspergillosis and invasive muko marcos's for adults.

Knight holds the rights to commercialize the product in all of Latin America and is an early launch Bays multiple countries, Argentina, Colombia Mexico, chile and Peru.

Knight also launched carpet in Argentina, which is indicated for relapsed and refractory multiple myeloma.

During the year night receive regulatory approval from Health Canada for the treatment of irritable bowel syndrome with constipation. It's rela was launched earlier this month. It is now covered by wage insurance companies in Canada.

Made also receive regulatory approval for both oxy.

We expect a launch both products in 2022 more over night is obtained regulatory approval for Alabama and Halliburton in Ecuador veeva has been approved for several indications and is used to treat patients with thyroid has cellular and advanced renal cell carcinomas.

I live in is used for the treatment of locally Advanced metastatic breast cancer and unresectable soft tissue sarcoma.

and Halliburton have both been launched in Brazil Argentina, Chile and Peru and we are